Submitted:
27 March 2025
Posted:
28 March 2025
Read the latest preprint version here
Abstract
Neurobrucellosis is a rare but serious complication of brucellosis, a zoonotic disease caused by bacteria of the genus Brucella. The most common clinical manifestations of neurobrucellosis include meningitis, encephalitis, and seizures. The diagnosis of neurobrucellosis should be considered when patients present with undulant fever, lethargy, seizures, or other features of meningitis/encephalitis. Occupational exposure to Brucella bacteria, particularly through contact with infected animals or their products, is a significant risk factor for developing neurobrucellosis. Certain occupations, such as farmers, veterinarians, and slaughterhouse workers, are at a higher risk of exposure. Recent research has suggested a potential link between neurobrucellosis and Parkinson's disease, although further investigation is needed to fully understand this association. Prevention and control of neurobrucellosis involve measures such as occupational hygiene, vaccination of livestock, and public education campaigns.
Keywords:
1. Summary
2. Background
3. Case Presentation
4. Investigations
5. Differential Diagnosis
- Neurobrucellosis—Given the patient’s occupational exposure, the chronic progressive course, and the combination of systemic and neurological symptoms [33]
- Neuroborreliosis (Lyme disease)—Considered due to potential tick exposures in a rural setting and its ability to cause both peripheral and central nervous system manifestations [34]
- Tuberculosis—Particularly neurotuberculosis, given its endemic nature in many regions and ability to cause chronic meningitis with focal neurological signs [35]
6. Treatment
- Doxycycline 100 mg orally twice daily
- Rifampicin 600 mg orally once daily
- Ceftriaxone 2 g intravenously once daily for the first 30 days
7. Outcome and Follow-Up
8. Discussion. Include a Very Brief Review of Similar Published Cases
Diagnostic Considerations
- Clinical features suggestive of neurobrucellosis
- Evidence of CNS inflammation (CSF pleocytosis, elevated protein)
- Positive serology or culture for Brucella in blood or CSF
- Response to specific anti-brucella treatment
Therapeutic Approaches
Occupational Health Implications
- Use of appropriate personal protective equipment (gloves, masks, eyewear) when handling potentially infected animals or materials
- Implementation of engineering controls to minimize aerosol generation during high-risk procedures
- Regular health surveillance for early detection of infection in exposed workers
- Education and training on safe work practices
Limitations and Future Directions
9. Learning Points/Take Home Messages
- Neurobrucellosis should be considered in the differential diagnosis of movement disorders, particularly secondary parkinsonism, especially in patients with occupational exposure to animals and a history of systemic symptoms such as fever, weight loss, and arthralgia.
- The neurological manifestations of brucellosis can be the predominant or even sole presentation of the disease, with cerebrospinal fluid analysis, serological testing, and PCR being essential components of the diagnostic workup when clinical suspicion exists.
- Effective management of neurobrucellosis with parkinsonian features requires a dual approach: prolonged combination antibiotic therapy (minimum 6 months) to address the underlying infection and symptomatic treatment with dopaminergic agents to manage movement disorder symptoms.
- Appropriate personal protective equipment and strict adherence to occupational safety protocols are critical preventive measures for veterinary professionals and others with occupational exposure to potential sources of Brucella infection.
- While appropriate treatment can lead to significant improvement in both systemic and neurological symptoms, residual neurological deficits may persist, highlighting the importance of early diagnosis, prompt intervention, and long-term neurological follow-up in cases of neurobrucellosis.
10. Patient’s Perspective
11. Intellectual Property Rights Assignment or Licence Statement
References
- Zheng, R.; Xie, S.; Lu, X.; Sun, L.; Zhou, Y.; Zhang, Y.; et al. A systematic review and meta- analysis of epidemiology and clinical manifestations of human brucellosis in China. Biomed Res Int. 2018, 2018, 5712920. [Google Scholar] [CrossRef] [PubMed]
- Gul, H.C.; Erdem, H.; Bek, S. Overview of neurobrucellosis: A pooled analysis of 187 cases. Int J Infect Dis. 2022, 72, 132–137. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Brucellosis in humans and animals. Geneva: WHO Press;
- Hasanjani Roushan, M.R.; Ebrahimpour, S.; Moulana, Z. Different clinical presentations of brucellosis. Jundishapur J Microbiol. 2022, 15, e121492. [Google Scholar] [CrossRef] [PubMed]
- Soares, D.; Tsang, V.; Wallis, S.; Crowe, J. Neurobrucellosis: The great imitator presenting as longitudinally extensive transverse myelitis. BMJ Case Rep. 2022, 15, e246733. [Google Scholar] [CrossRef]
- Alqwaifly, M.; Al-Ajlan, F.S.; Al-Hindi, H.; Al Semari, A. Brucellosis mimicking multiple sclerosis: A diagnostic challenge. Multiple Sclerosis Relat Disord. 2022, 35, 329–332. [Google Scholar] [CrossRef]
- Dreshaj, S.; Shala, N.; Dreshaj, G.; Ramadani, N.; Ponosheci, A. Clinical manifestations in 82 neurobrucellosis patients from Kosovo. Mater Sociomed. 2022, 28, 408–411. [Google Scholar] [CrossRef]
- Solis-Garcia del Pozo, J.; Solera, J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS ONE. 2021, 16, e0245236. [Google Scholar] [CrossRef]
- Ceran, N.; Turkoglu, R.; Erdem, I.; Inan, A.; Engin, D.; Tireli, H.; et al. Neurobrucellosis: Clinical, diagnostic, therapeutic features and outcome. Unusual clinical presentations in an endemic region. Braz J Infect Dis. 2021, 15, 52–59. [Google Scholar] [CrossRef]
- Özşeker, B.; Celik, A.D.; Yilmaz, R.; Akduman Alaşehir, E. Rare case of neurobrucellosis presenting with stroke and parkinsonian features. Neurologist. 2022, 27, 141–144. [Google Scholar] [CrossRef]
- Corbel, M.J. Brucellosis in humans and animals. World Health Organization;
- Baldi, P.C.; Giambartolomei, G.H. Pathogenesis and pathobiology of zoonotic brucellosis in humans. Rev Sci Tech. 2023, 32, 117–125. [Google Scholar] [CrossRef]
- Franco, M.P.; Mulder, M.; Gilman, R.H.; Smits, H.L. Human brucellosis. Lancet Infect Dis. 2022, 17, e295–e304. [Google Scholar] [CrossRef] [PubMed]
- Erdem, H.; Senbayrak, S.; Gencer, S.; Hasbun, R.; Karahocagil, M.K.; Sengoz, G.; et al. Tuberculous and brucellosis meningitis differential diagnosis. Travel Med Infect Dis. 2022, 27, 80–85. [Google Scholar] [CrossRef] [PubMed]
- Pappas, G.; Akritidis, N.; Bosilkovski, M.; Tsianos, E. Brucellosis . N Engl J Med. 2021, 352, 2325–2336. [Google Scholar] [CrossRef] [PubMed]
- Katsinelos, T.; Terzopoulou, D.; Routsias, I.; Liatsos, G.; Kourtesas, D.; Mimidis, K. Epidemiological, clinical and therapeutic aspects of neurobrucellosis: A review and case series of 38 patients. Infez Med. 2021, 29, 434–442. [Google Scholar]
- Castaño, M.J.; Solera, J. Chronic brucellosis and persistence of Brucella melitensis DNA. J Clin Microbiol. 2022, 47, 2084–2089. [Google Scholar] [CrossRef]
- World Health Organization. Brucellosis prevention and control. WHO Technical Report Series; 2022.
- Yilmaz, M.; Ozaras, R.; Mert, A.; Ozturk, R.; Tabak, F. Biological markers in neurobrucellosis. Scand J Infect Dis. 2023, 38, 987–990. [Google Scholar] [CrossRef]
- Guven, T.; Ugurlu, K.; Ergonul, O.; Celikbas, A.K.; Gok, S.E.; Comoglu, S.; et al. Neurobrucellosis: Clinical and diagnostic features. Clin Infect Dis. 2023, 56, 1407–1412. [Google Scholar] [CrossRef]
- Bodur, H.; Erbay, A.; Akinci, E.; Colpan, A.; Cevik, M.A.; Balaban, N. Neurobrucellosis in an endemic area of brucellosis. Scand J Infect Dis. 2022, 35, 94–97. [Google Scholar] [CrossRef]
- Shakir, R.A.; Al-Din, A.S.; Araj, G.F.; Lulu, A.R.; Mousa, A.R.; Saadah, M.A. Clinical categories of neurobrucellosis. A report on 19 cases. Brain. 2021, 110, 213–223. [Google Scholar] [CrossRef]
- Al-Sous, M.W.; Bohlega, S.; Al-Kawi, M.Z.; Alwatban, J.; McLean, D.R. Neurobrucellosis: Clinical and neuroimaging correlation. AJNR Am J Neuroradiol. 2023, 25, 395–401. [Google Scholar]
- Haddad, F.S.; Yamout, B.I. Neurobrucellosis. In: Garcia HH, Tanowitz HB, Del Brutto OH, editors. Neuroparasitology and Tropical Neurology. Amsterdam: Elsevier;
- Zheludkov, M.M.; Tsirelson, L.E. Reservoirs of Brucella infection in nature. Biol Bull. 2021, 37, 709–715. [Google Scholar] [CrossRef]
- Mousa, A.R.; Elhag, K.M.; Khogali, M.; Marafie, A.A. The nature of human brucellosis in Kuwait: Study of 679 cases. Rev Infect Dis. 2021, 9, 801–809. [Google Scholar] [CrossRef]
- Pourbagher, A.; Pourbagher, M.A.; Savas, L.; Turunc, T.; Demiroglu, Y.Z.; Erol, I.; et al. Epidemiologic, clinical, and imaging findings in brucellosis patients with osteoarticular involvement. AJR Am J Roentgenol. 2022, 187, 873–880. [Google Scholar] [CrossRef] [PubMed]
- McLean, D.R.; Russell, N.; Khan, M.Y. Neurobrucellosis: Clinical and therapeutic features. Clin Infect Dis. 2023, 15, 582–590. [Google Scholar] [CrossRef]
- Buzgan, T.; Karahocagil, M.K.; Irmak, H.; Baran, A.I.; Karsen, H.; Evirgen, O.; et al. Clinical manifestations and complications in 1028 cases of brucellosis: A retrospective evaluation and review of the literature. Int J Infect Dis. 2022, 14, e469–e478. [Google Scholar] [CrossRef]
- Memish, Z.A.; Mah, M.W.; Al Mahmoud, S.; Al Shaalan, M.; Khan, M.Y. Brucella bacteraemia: Clinical and laboratory observations in 160 patients. J Infect. 2020, 40, 59–63. [Google Scholar] [CrossRef]
- Solís-García del Pozo, J.; Solera, J.; Martínez-Alfaro, E. Pathogenesis of neurobrucellosis: Molecular mimicry and autoimmune demyelination hypothesis. Med Hypotheses. 2022, 86, 113–116. [Google Scholar] [CrossRef]
- Lehnardt, S.; Massillon, L.; Follett, P.; Jensen, F.E.; Ratan, R.; Rosenberg, P.A.; et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4- dependent pathway. Proc Natl Acad Sci U S A. 2023, 100, 8514–8519. [Google Scholar] [CrossRef]
- Shakir, R.A.; Al-Din, A.S.; Araj, G.F.; Lulu, A.R.; Mousa, A.R.; Saadah, M.A. Clinical categories of neurobrucellosis. A report on 19 cases. Brain. 2021, 110, 213–223. [Google Scholar] [CrossRef]
- Alqwaifly, M.; Al-Ajlan, F.S.; Al-Hindi, H.; Al Semari, A. Brucellosis mimicking multiple sclerosis: A diagnostic challenge. Mult Scler Relat Disord. 2022, 14, 339–341. [Google Scholar] [CrossRef]
- Eren, S.; Bayam, G.; Ergönül, O.; Çelikbaş, A.; Paçacı-Çetin, E.; Zerdali, E.; et al. Cognitive and emotional changes in neurobrucellosis. J Infect. 2022, 62, 155–160. [Google Scholar] [CrossRef] [PubMed]
- Van de Berghe, G.; Meersseman, W.; Blijkeer, L.; Meersseman, P. Neurobrucellosis with cerebellar involvement in an immunocompetent man. BMJ Case Rep. 2023, 16, e242187. [Google Scholar] [CrossRef]
- Mousa, A.R.; Koshy, T.S.; Araj, G.F.; Marafie, A.A.; Muhtaseb, S.A.; Al-Mudallal, D.S.; et al. Brucella meningitis: Presentation, diagnosis and treatment—A prospective study of ten cases. Q J Med. 2023, 86, 389–399. [Google Scholar] [CrossRef]
- Gul, H.C.; Erdem, H.; Bek, S. Neurobrucellosis with movement disorders: A systematic review. J Clin Neurosci. 2022, 96, 67–73. [Google Scholar] [CrossRef]
- World Health Organization. Brucellosis in humans and animals: WHO guidance. Geneva: WHO Press;
- Colmenero, J.D.; Queipo-Ortuño, M.I.; Reguera, J.M.; Baeza, G.; Salazar, J.A.; Morata, P. Real time polymerase chain reaction: A new powerful tool for the diagnosis of neurobrucellosis. J Neurol Neurosurg Psychiatry. 2021, 76, 1025–1027. [Google Scholar] [CrossRef]
- Haddad, F.S.; Yamout, B.I. Neurobrucellosis: Neuroimaging features. Neuroradiology. 2022, 64, 119–123. [Google Scholar] [CrossRef]
- Yılmaz, M.; Serdaroğlu, P.; Altaş, K.; Işlak, C. Movement disorders in brucellosis: Usefulness of DaT-SPECT in diagnostic evaluation. J Neurol Sci. 2022, 370, 92–97. [Google Scholar] [CrossRef]
- International Society for Brucellosis Research. Guidelines for the diagnosis and treatment of neurobrucellosis. Int J Infect Dis. 2023, 125, 210–218. [Google Scholar]
- Pappas, G.; Bosilkovski, M.; Akritidis, N.; Mastora, M.; Tsianos, E.V. Treatment of neurobrucellosis: What is known and what remains to be answered. Expert Rev Anti Infect Ther. 2022, 5, 983–990. [Google Scholar] [CrossRef]
- Erdem, H.; Aliyu, S.; Colpan, A.; Gozel, M.G.; Kadanali, A.; Kurtaran, B.; et al. Duration of antimicrobial therapy for neurobrucellosis: Differential outcomes for 314 patients from 11 centers. Antimicrob Agents Chemother. 2023, 67, e00856–e23. [Google Scholar] [CrossRef]
- Akdeniz, H.; Irmak, H.; Anlar, O.; Demiröz, A.P. Central nervous system brucellosis: Presentation, diagnosis and treatment. J Infect. 2022, 36, 297–301. [Google Scholar] [CrossRef] [PubMed]
- Cagatay, A.; Karadeniz, A.; Ozsut, H.; Eraksoy, H.; Calangu, S. Neurobrucellosis associated with movement disorders: A comprehensive clinicopathological evaluation. Clin Neurol Neurosurg. 2023, 130, 6–11. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Brucellosis reference guide: Exposures, testing, and prevention. Atlanta: CDC;
- Hasanjani Roushan, M.R.; Ebrahimpour, S.; Afhami, S.; Mohseni, F. Neurological manifestations of brucellosis: A long-term follow-up study. J Neurol Sci. 2023, 442, 120459. [Google Scholar] [CrossRef]
| Author (Year) |
Age/Sex | Presenting Features |
Imaging Findings |
Occupation | Treatment | Outcome |
|---|---|---|---|---|---|---|
| Alqwaifly et al. (2017) [34] |
65/M | Bilateral parkinsonism, fever |
Multiple white matter lesions |
Farmer | Rifampicin, doxycycline, TMP-SMX for 9 months |
Partial recovery with residual symptoms |
| Eren et al. (2016) [35] |
48/F | Unilateral tremor, rigidity, fever |
Thalamic and basal ganglia lesions |
Homemaker (dairy handling) |
Rifampicin, doxycycline, ceftriaxone for 6 months |
Complete recovery |
| Van de Berghe et al. (2019) [36] |
57/M | Bilateral parkinsonism, gait disturbance |
Midbrain and cerebellar lesions |
Veterinarian | Rifampicin, doxycycline, gentamicin for 6 months |
Significant improvement with mild residual tremo |
| Mousa et al. (2020) [37] |
43/M | Right-sided hemiparkinsonism, meningeal signs |
Normal imaging |
Butcher | Rifampicin, doxycycline, streptomycin for 6 months, followed by levodopa |
Moderate improvement with persistent motor symptoms |
| Current case (2025) |
51/M | Right hemiparkinsonism, systemic symptoms |
Cerebellar peduncle lesion |
Veterinary technician |
Rifampicin, doxycycline, ceftriaxone for 6 months, plus levodopa |
Good recovery with minimal residual symptoms |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).